Literature DB >> 16550752

Lamivudine for nephrotic syndrome related to hepatitis B virus (HBV) infection.

N Kanaan1, Y Horsmans, E Goffin.   

Abstract

A 57-year-old man presented with nephrotic syndrome associated with active HBV infection. Liver biopsy showed severe portal and moderate lobular inflammation, patchy necrosis, moderate fibrosis and several "ground glass" cells. Immunofluorescence microscopical view of the renal biopsy showed diffuse granular IgG deposits along the glomerular basement membrane, compatible with MN. As symptomatic therapy with ACE inhibitors did not improve the nephrotic syndrome, lamivudine 100 mg o.d. was initiated. HBV-DNA became undetectable after 10 weeks and seroconversion of HBeAg and HBsAg to anti-HBe and anti-HBs occurred after 2 additional months; proteinuria normalized subsequently. This observation documents for the first time in an adult the beneficial effect of lamivudine in glomerulonephritis related to HBV infection with HBV seroconversion and complete remission of the nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16550752     DOI: 10.5414/cnp65208

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  9 in total

Review 1.  Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis.

Authors:  Xiao-Yong Zheng; Ri-Bao Wei; Li Tang; Ping Li; Xiao-Dong Zheng
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

2.  Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis.

Authors:  Yu Zhang; Jian-Hua Zhou; Xiao-Ling Yin; Feng-Yu Wang
Journal:  World J Gastroenterol       Date:  2010-02-14       Impact factor: 5.742

3.  Posterior reversible encephalopathy syndrome in a patient with hepatitis B induced type 1 membranoproliferative glomerulonephritis.

Authors:  Vishwanath Sathyanarayanan; Abdul Razak; Girish Narayan; Mukhyaprana Prabhu; Balasubramanian Ramachandran; Kudva Ranjini; Monappa Vidya; Kusum Joshi
Journal:  Clin Exp Nephrol       Date:  2010-08-21       Impact factor: 2.801

4.  Steroid treatment in patients with membranous nephropathy and hepatitis B virus surface antigenemia: a report of two cases.

Authors:  Tetsu Akimoto; Toshiya Otake; Akira Tanaka; Hideaki Takahashi; Toshihiko Higashizawa; Makoto Inoue; Katsuhiko Nishino; Osamu Saito; Norio Isoda; Shigeaki Muto; Kentaro Sugano; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2010-12-18       Impact factor: 2.801

5.  Membranous nephropathy associated with viral infection.

Authors:  Aikaterini Nikolopoulou; Catarina Teixeira; H Terry Cook; Candice Roufosse; Thomas H D Cairns; Jeremy B Levy; Charles D Pusey; Megan E Griffith
Journal:  Clin Kidney J       Date:  2020-04-15

6.  Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection.

Authors:  Akihiko Numata; Tetsu Akimoto; Masaki Toshima; Yoshitaka Iwazu; Naoko Otani; Takuya Miki; Taro Sugase; Osamu Saito; Yoshitomo Hamano; Fumi Takemoto; Yoshihiko Ueda; Shigeaki Muto; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2011-06-29       Impact factor: 2.617

Review 7.  Hepatitis B virus associated focal and segmental glomerular sclerosis: report of two cases and review of literature.

Authors:  Ambar Khaira; Bala Krishna Upadhyay; Alok Sharma; Prasenjit Das; Sandeep Mahajan; Govind Makhariya; Amit K Dinda; Sanjay K Agarwal; Suresh C Tiwari
Journal:  Clin Exp Nephrol       Date:  2009-01-24       Impact factor: 2.617

8.  Association of acute tubular necrosis with gross hematuria in cirrhosis-related immunoglobulin A nephropathy.

Authors:  Jang Soo Han; So Dug Lim; Won Hyeok Choi; Sung Chul Hong; Jung Hee Park; Eugene Park; Mi Jin Hong; Cho I Lee; Jung Hwan Park; Jong Ho Lee; Jong Oh Song; Young Il Jo
Journal:  Kidney Res Clin Pract       Date:  2013-01-02

9.  Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study.

Authors:  Zhaoping Yan; Bing Qiao; Haifeng Zhang; Yanling Wang; Wei Gou
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.